ExodusPoint Capital Management’s Ocular Therapeutix OCUL Stock Holding History

ExodusPoint Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-163,132	Closed	-$1.91M	–	1916
2025 Q3	$1.91M	Buy	+163,132	New	+$1.95M	0.02%	747
2025 Q2	–	Sell	-96,185	Closed	-$705K	–	1838
2025 Q1	$705K	Buy	+96,185	New	+$739K	0.01%	1018
2023 Q4	–	Sell	-98,422	Closed	-$309K	–	1884
2023 Q3	$309K	Buy	+98,422	New	+$403K	﹤0.01%	1413
2022 Q4	–	Sell	-13,402	Closed	-$56K	–	1982
2022 Q3	$56K	Buy	+13,402	New	+$67.5K	﹤0.01%	1791
2022 Q2	–	Sell	-11,306	Closed	-$56K	–	2292
2022 Q1	$56K	Buy	+11,306	New	+$62.7K	﹤0.01%	2054
2021 Q4	–	Sell	-13,662	Closed	-$137K	–	2476
2021 Q3	$137K	Buy	13,662 +3,561	+35%	+$40K	﹤0.01%	1856
2021 Q2	$143K	Buy	+10,101	New	+$154K	﹤0.01%	2071

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ExodusPoint Capital Management's OCUL Position: Q4 2025 in Review

ExodusPoint Capital Management sold out of Ocular Therapeutix (OCUL) in Q4 2025, closing a stake of 163,132 shares — an estimated $1.91M sold.

ExodusPoint Capital Management first reported a position in OCUL in Q2 2021 and held it in 7 quarters. The position peaked at $1.91M in Q3 2025. 249 funds tracked by Wall St. Rank hold OCUL as of Q4 2025.

ExodusPoint Capital Management reported no remaining Ocular Therapeutix position as of Q4 2025 after selling out during the quarter.
ExodusPoint Capital Management sold 163,132 Ocular Therapeutix shares in Q4 2025, an estimated $1.91M.
ExodusPoint Capital Management first reported a position in Ocular Therapeutix in Q2 2021 and held it in 7 quarters.
ExodusPoint Capital Management's Ocular Therapeutix position peaked at $1.91M in Q3 2025.
249 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2025.

Based on ExodusPoint Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.